NASDAQ$RNA

Atrium Therapeutics Inc · Q3 2025 earnings

Q3 2025 earnings ·

Briefing

RNA Q3 2025 — $2.3M revenue, 1.27 EPS

Any of these actions could materially harm the Company’s business, results of operations and future prospects. Atrium Therapeutics Inc reported Q3 2025 results. Diluted EPS came in at $1.27. Headline numbers extracted from the Form 10-Q press release; narrative is light because this row was processed without an LLM call.

  • Revenue: $2.3M.
  • Diluted EPS: $1.27.
  • Filed on Form 10-Q (accession 0001599901-25-000210).

Headline financials

Total Revenue

$12.5M

Previous: $2.34M+434.0%
EPS (adj)

$1.27

Previous: -$0.65+295.4%
Capital Expenditures

-$7.81M

Previous: -$3.15M-147.9%
Free Cash Flow

-$182M

Previous: -$83.5M-118.1%
Net Income

-$174M

Previous: -$80.4M-117.0%
Operating Income

-$189M

Previous: -$98.1M-92.4%

Revenue & EPS history

Atrium Therapeutics Inc · Revenue · Quarterly

$12.5M

Q3 2025+434%vs Q3 2024
Beat estimate in 1 of 1 quarters(100%)
ActualEstimate

Revenue by segment

Atrium Therapeutics Inc · $19.6M total across 1 segment · Q1 2026

  • Reportable Segment
    $19.6M—

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro